-
Chronic hypertension and adverse pregnancy outcomes: a cohort study.
Panaitescu AM, Syngelaki A, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:228-235. pdf -
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;36:106-16.. pdf -
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
Bujold E, Roberge S, Nicolaides KH.
Prenat Diagn 2014;34:642-8. pdf -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85. -
Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, down's syndrome, preterm delivery and preeclampsia.
Chambers AE, Griffin C, Naif SA, Mills I, Mills WE, Syngelaki A, Nicolaides KH, Banerjee S.
Reprod Biol Endocrinol 2012;10:113. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Early vaginal bleeding has no impact on markers used in first trimester aneuploidy screening.
Spencer K, Spencer CE, Stamatopoulou A, Staboulidou I, Nicolaides KH.
Prenat Diagn 2010;30:547-50. -
First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers.
Spencer K, Staboulidou I, Nicolaides KH.
Prenat Diagn 2010;30:235-40. -
Additional first-trimester ultrasound markers.
Sonek J, Nicolaides K.
Clin Lab Med 2010;30:573-92. -
Outcome of pregnancies with trisomy 2 cells in chorionic villi.
Sifakis S, Staboulidou I, Maiz N, Velissariou V, Nicolaides KH.
Prenat Diagn 2010;30:329-32. -
Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies.
Sifakis S, Akolekar R, Syngelaki A, Cruz JJ, Nicolaides KH.
Prenat Diagn 2010;30:212-5. -
Nasal bone length in euploid fetuses at 16-24 weeks of gestation by three-dimensional ultrasound.
Persico N, Molina F, Borenstein M, Azumendi G, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;36:285-90. -
Normal ranges of embryonic length, embryonic heart rate, gestational sac diameter and yolk sac diameter at 6-10 weeks.
Papaioannou GI, Syngelaki A, Poon LC, Ross JA, Nicolaides KH.
Fetal Diagn Ther 2010;28:207-19. -
Semi-automated system for the measurement of nuchal translucency thickness.
Moratalla J, Pintoffl K, Minekawa R, Lachmann R, Wright D, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:412-6. -
Ductus venosus in the first trimester: contribution to screening of chromosomal, cardiac defects and monochorionic twin complications.
Maiz N, Nicolaides KH.
Fetal Diagn Ther 2010;28:65-71. -
The 11-13-week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis.
Kagan KO, Staboulidou I, Syngelaki A, Cruz JJ, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;36:10-4.